Home › Research › Topics › intestinal
intestinal
273 studies tagged intestinal, dated 1995-01-01 to 2026-10-23. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Evidence that the perinatal maternal microbiome mediates metabolite signaling programs that drive sex-specific microglial metabolic alterations and Alzheimer’s disease susceptibility 2026-10-23
- Change in gut microbiome precedes symptomatic Alzheimer’s disease and is correlated with amyloid-beta accumulation in the brain 2026-10-19
- The Gut–Liver–Brain Axis in Neurodegeneration: Unraveling Metabolic–Immune Crosstalk from Peripheral Sensing to Central Vulnerability 2026-10-08
Studies
273 studies carry this tag.
Date range
1995 to 2026
Top journals
- Journal of Alzheimer's disease : JAD 13
- Scientific reports 8
- Nutrients 7
- Brain, behavior, and immunity 6
- Frontiers in cellular and infection microbiology 6
168 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
An essential regulator of neurodegenerative conditions like Alzheimer's disease (AD) is the gut microbiota.
-
Regulating the gut flora ecological balance upregulates neurotrophic factor expression, regulates the microbiota-gut-brain (MGB) axis, and suppresses the inflammatory responses.
-
Trillions of microbes live symbiotically in the host, specifically in mucosal tissues such as the gut.
-
45/100
Alzheimer's disease (AD) is a fatal progressive neurodegenerative disease.
-
There were 20 positive and 16 negative causal effects between genetic liability in the gut microbiota and dementia.
-
Alzheimer's disease (AD) is the most prevalent type of dementia, but its etiopathogenesis is not yet fully understood.
-
Neurodegenerative diseases are caused by the loss of neurons and/or their myelin sheaths, which deteriorate over time and become dysfunctional.
-
JOURNAL/nrgr/04.03/01300535-202410000-00029/figure1/v/2024-02-06T055622Z/r/image-tiff Disturbances in the microbiota-gut-brain axis may contribute to the development of Alzheimer's disease.
-
Disturbances in the local and peripheral immune systems are closely linked to a wide range of diseases.
-
47/100
Alzheimer's disease is a complex neurodegenerative disorder leading to a decline in cognitive function and mental health.
-
45/100
Alzheimer's disease (AD) is characterized by amyloid-β accumulation in the brain and hyperphosphorylated tau aggregation, as well as neuroinflammation.
-
The advent of high-throughput 'omics' technologies has improved our knowledge of gut microbiome in human health and disease, including Alzheimer's disease (AD), a neurodegenerative disorder.
-
The gut microbiome plays a pivotal role in maintaining human health, with numerous studies demonstrating that alterations in microbial compositions can significantly affect the development and progression of various immune-mediated diseases affecting both the digestive tract and the central nervous system (CNS).
-
Inflammatory Bowel Disease (IBD), a chronic nonspecific intestinal inflammatory disease, is comprised of Ulcerative Colitis (UC) and Crohn's Disease (CD).
-
The microbiota-gut-brain axis refers to the intricate bidirectional communication between commensal microorganisms residing in the digestive tract and the central nervous system, along neuroendocrine, metabolic, immune, and inflammatory pathways.
-
Increasing research links the gut microbiome to neurodegenerative disorders.
-
The gut microbiota (GM) plays an important role in the physiology and pathology of the host.
-
The multifaceted microbiota characterizing our gut plays a crucial role in maintaining immune, metabolic and tissue homeostasis of the intestine as well as of distal organs, including the central nervous system.
-
In the last decade, the role of the microbiota-gut-brain axis has been gaining momentum in the context of many neurodegenerative and metabolic disorders, including Alzheimer's disease (AD) and diabetes, respectively.
-
The evolution of the understanding of the intestinal microbiota and its influence on our organism leverages it as a potential protagonist in therapies aimed at diseases that affect not only the intestine but also neural pathways and the central nervous system itself.
-
Alzheimer's disease (AD) pathology is thought to progress from normal cognition through preclinical disease and ultimately to symptomatic AD with cognitive impairment.
-
Alzheimer's disease (AD) is a neurodegenerative disease characterized by dementia and the accumulation of amyloid beta in the brain.
-
Alzheimer's disease (AD), is a chronic age-related progressive neurodegenerative disorder, characterized by neuroinflammation and extracellular aggregation of Aβ peptide.
-
Alzheimer's disease (AD) is the most common type of dementia in the elderly and causes neurodegeneration, leading to memory loss, behavioral disorder, and psychiatric impairment.
-
Probiotic supplements were shown to improve cognitive function in Alzheimer's disease (AD) patients.
-
Clinical and animal studies have shown that gut microbiome disturbances can affect neural function and behaviors via the microbiota-gut-brain axis, and may be implicated in the pathogenesis of several brain diseases.
-
Gut microbiota represents a diverse and dynamic population of microorganisms harbouring the gastrointestinal tract, which influences host health and disease.
-
Mitochondria are highly dynamic organelles that serve as the primary cellular energy-generating system.
-
Tau-mediated neurodegeneration is a hallmark of Alzheimer's disease.
-
The composition of the gut microbiota influences the CNS, resulting in changes in host behavior and may be related to the development of neurodegenerative diseases.
-
Peripheral β-amyloid (Aβ), including those contained in the gut, may contribute to the formation of Aβ plaques in the brain, and gut microbiota appears to exert an impact on Alzheimer's disease (AD) via the gut-brain axis, although detailed mechanisms are not clearly defined.
-
Microbial-derived metabolites are the intermediate or end products of bacterial digestion.
-
Lewy body diseases, such as Parkinson's disease and dementia with Lewy bodies, vary in their clinical phenotype but exhibit the same defining pathological feature, α-synuclein aggregation.
-
The intestinal barrier, which primarily consists of a mucus layer, an epithelial barrier, and a gut vascular barrier, has a crucial role in health and disease by facilitating nutrient absorption and preventing the entry of pathogens.
-
Initial studies suggested that the fluctuations in the quantity, variety, and composition of the gut microbiota can significantly affect disease processes.
-
The highest density of microbes resides in human gastrointestinal tract, known as "Gut microbiome".
-
Alzheimer's disease (AD) is the most prevalent form of dementia and can be influenced by genetic and environmental factors.
-
The gut-brain axis describes a bidirectional interplay within the enteric environment between the intestinal epithelium, the mucosal immune system, and the microbiota with the enteric nervous system.
-
An epidemic of age-associated cognitive decline, most commonly ascribed to neurodegenerative conditions such as Alzheimer's and Parkinson's disease, is causing healthcare costs to soar and devastating caregivers.
-
Huntington's disease is a neurodegenerative disorder involving psychiatric, cognitive and motor symptoms.
-
Gut microbiota alterations might affect the development of Alzheimer's disease (AD) through microbiota-derived metabolites.
-
Short-chain fatty acids (SCFAs) are important metabolites derived from the gut microbiota through fermentation of dietary fiber.
-
Hundreds of billions of commensal microorganisms live in and on our bodies, most of which colonize the gut shortly after birth and stay there for the rest of our lives.
-
Alzheimer's disease (AD) and related dementias (ADRD) are still a serious global public health concern more than a century after the German neuropathologist and psychiatrist Dr. Aloysius Alzheimer described the first case.
-
70/100
The results showed that intestinal expression of GLP-1 1 could reduce the intestinal pathogenic genus such as Enterobacteriaceae and was obviously associated with a greater number of beneficial genera such as Lactobacillus and Akkermansia.
-
These findings demonstrate that the aging gut microbiota drives detrimental changes in the gut-brain and gut-retina axes suggesting that microbial modulation may be of therapeutic benefit in preventing inflammation-related tissue decline in later life.
-
Emerging evidence suggests that both disruption of circadian rhythms and gut dysbiosis are closely related to aging-associated neurodegenerative diseases.
-
It has been noticed in recent years that the unfavorable effects of the gut microbiota could exhaust host vigor and life, yet knowledge and theory are just beginning to be established.
-
Over the last 10 years, there has been a growing interest in the relationship between gut microbiota, the brain, and neurologic-associated affections.
-
Microbial flora is investigated to be related with neuropathological conditions in Alzheimer's disease (AD), and is attracting attention as a drug discovery resource.
From across this tag
8 of the 273 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
- Lactobacilli and bifidobacteria ameliorate memory and learning deficits and oxidative stress in β-amyloid (1-42) injected rats
- The Gut Microbiome and Alzheimer's Disease: A Growing Relationship
- Effects of gut microbiota and probiotics on Alzheimer's disease
- Changes of Colonic Bacterial Composition in Parkinson's Disease and Other Neurodegenerative Diseases
- Brain-Gut and Microbiota-Gut-Brain Communication in Type-2 Diabetes Linked Alzheimer's Disease
- Microbiota-Gut-Brain Axis and Epilepsy: A Review on Mechanisms and Potential Therapeutics
- Probiotic Supplementation Improves Cognitive Function and Mood with Changes in Gut Microbiota in Community-Dwelling Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
- Fructooligosaccharides Ameliorating Cognitive Deficits and Neurodegeneration in APP/PS1 Transgenic Mice through Modulating Gut Microbiota